PharmaMar S.A.
Pol Ind. la Mina Avenida de los Reyes, 1
Colmenar Viejo
Madrid
28770
Tel: 34-91-8466000
Fax: 34-91-8466001
Website: http://www.pharmamar.com/
Email: pharmamar@pharmamar.com
103 articles about PharmaMar S.A.
-
PharmaMar S.A. Announces The Start Of A Pivotal Study With Plitidepsin In Angioimmunoblastic T-Cell Lymphoma
6/15/2016
-
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation
2/8/2016
-
PharmaMar S.A. And Specialised Therapeutics Asia Sign Licensing And Marketing Agreement For APLIDIN (plitidepsin) Covering Several Asian Countries
2/2/2016
-
PharmaMar S.A. Sets Up Unit In London
9/15/2015
-
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers
7/23/2015
-
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer
6/29/2015
-
Myriad Genetics, Inc. Partners With PharmaMar S.A. for New HRD Test
3/29/2013
-
Spanish Biotech PharmaMar S.A. Selects Medidata Solutions, Inc. Clinical Cloud to Accelerate Trials for Marine-Based Oncology Drugs
3/18/2013
-
PharmaMar S.A. Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
2/8/2011
-
PharmaMar S.A. Initiates a Phase III Registration Trial with Aplidin(R) in Multiple Myeloma Patients
6/9/2010
-
PharmaMar S.A. Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
4/22/2010
-
Zeltia Group's PharmaMar S.A. in Deal With US Medimetriks Pharmaceuticals, Inc.
6/10/2009
-
Innovex to Promote PharmaMar S.A.'s Yondelis(R) Cancer Treatment
12/3/2007
-
Dr. Enrique Sendagorta Appointed Managing Director Of PharmaMar S.A.
1/19/2007
-
PharmaMar S.A. Release: Successful Planned Independent Analysis Of Pivotal Phase III Trial Of YONDELIS® In Ovarian Cancer
10/5/2006
-
PharmaMar S.A. Reports New Data On Kahalalide-F And Aplidin(R) At ESMO Congress
9/28/2006
-
PharmaMar Submits Marketing Authorization Application In Europe For Yondelis(R) In Soft Tissue Sarcoma
7/27/2006
-
Johnson and Johnson Pharmaceutical R&D (NJ) Release: Update On Regulatory Filing Plans For Investigational Compound Trabectedin In Soft Tissue Sarcoma
6/1/2006
-
PharmaMar S.A. Highlights Aplidin(R) Results At American Association for Cancer Research
4/4/2006
-
PharmaMar S.A. Release: FDA Grants IND For FDA's ZALYPSISÒ To Enter Phase I Clinical Trials In US
1/31/2006